Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Short term Debt (2016 - 2019)

Fate Therapeutics' Short term Debt history spans 8 years, with the latest figure at $13.9 million for Q3 2019.

  • For Q3 2019, Short term Debt rose 326.84% year-over-year to $13.9 million; the TTM value through Sep 2019 reached $13.9 million, up 326.84%, while the annual FY2018 figure was $2.4 million, N/A changed from the prior year.
  • Short term Debt reached $13.9 million in Q3 2019 per FATE's latest filing, up from $5.4 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $13.9 million in Q3 2019 to a low of $758000.0 in Q1 2018.
  • Average Short term Debt over 5 years is $5.9 million, with a median of $6.0 million recorded in 2015.
  • Peak YoY movement for Short term Debt: soared 962.85% in 2015, then tumbled 90.05% in 2018.
  • A 5-year view of Short term Debt shows it stood at $7.6 million in 2015, then increased by 8.44% to $8.2 million in 2016, then decreased by 6.93% to $7.6 million in 2017, then tumbled by 68.01% to $2.4 million in 2018, then soared by 471.45% to $13.9 million in 2019.
  • Per Business Quant, the three most recent readings for FATE's Short term Debt are $13.9 million (Q3 2019), $5.4 million (Q2 2019), and $3.9 million (Q1 2019).